ClinicalTrials.gg
RecruitingNCT07386444IMACTUpdated Apr 6, 2026

Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy

An interventional study of Inspiratory muscle training in Early Stage Breast Carcinoma and Dyspnea, sponsored by Ohio State University Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Ohio State University Comprehensive Cancer Center · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 214 studies in Dyspnea with a site in United States — 31 open to participants now, 37 under way, 1 of them phase 3. Dyspnea · United States.

Planned enrollment
63rd of 151
58 · median 36
Started
2026
with 10 others
No phase
84 of 214
18 open now
Primary completion
2026-12
later than 11 of 36 live
Registered
204th of 214
by date

Among the 214 studies in Dyspnea with a site in United States, this one is the 63rd largest by planned enrollment of the 151 interventional ones that give a count, is one of 11 that started in 2026, is one of 84 with no phase, reaches primary completion later than 11 of the 36 other live ones, and was the 204th registered.

Dyspnea

895 studies on the registry are indexed under Dyspnea; 189 are open to participants now.

Browse Dyspnea studies →

Open to participants now

31 of the 214 studies in Dyspnea with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 125 Dyspnea studies recruiting now, 68 (54%) set no upper age limit and 41 (33%) stop at 75 or younger; 18 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies in Dyspnea with a site in United States, or all of them as a file.
02

Study summary

This clinical trial studies whether breathing exercises for the muscles that help with breathing air in, inspiratory muscle training (IMT), works to improve breathing muscle strength, shortness of breath, and physical activity levels in women who are receiving chemotherapy for early-stage breast cancer (BC). Cancer and/or treatments for BC can directly result in muscle wasting that involves breathing muscles, skeletal muscles or heart muscles. Pain, weakness, shortness of breath, and side effects of cancer treatment may lead to lower physical activity levels. IMT involves breathing exercises using a small hand-held device. The device makes it a little harder to breathe in, which may help strengthen breathing muscles. IMT may be an effective way to improve breathing muscle strength, shortness of breath, and physical activity levels in women who are receiving chemotherapy for early-stage BC.

Read the detailed description

PRIMARY OBJECTIVE: To investigate the effects of 8 weeks of IMT on inspiratory muscle strength, exertional dyspnea, and physical activity levels among women undergoing chemotherapy for BC.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM 1: Patients complete three sets of fifteen repetitions per session of low-intensity IMT over 15-20 minutes four days a week for 8 weeks.

ARM 2: Patients complete three sets of fifteen repetitions per session of high-intensity IMT over 15-20 minutes four days a week for 8 weeks.

03

Conditions studied

  • Early Stage Breast Carcinoma
  • Dyspnea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Within 3 weeks of starting chemotherapy for an early-stage breast cancer diagnosis
  • Able to exercise independently without needing support
  • Ability to read, speak, understand English

Exclusion criteria

Exclusion Criteria:

  • breast cancer
  • Unwilling or unable to follow protocol requirements
  • Any significant health condition which in the investigator's opinion increases the risks of participation or makes the participant unsuitable for the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
58 participants (estimated)

Study arms

  • Active comparator
    Arm 1 (low-intensity IMT)

    Patients complete three sets of fifteen repetitions per session of low-intensity IMT over 15-20 minutes four days a week for 8 weeks.

    Behavioral: Inspiratory muscle training

  • Experimental
    Arm 2 (high-intensity IMT)

    Patients complete three sets of fifteen repetitions per session of high-intensity IMT over 15-20 minutes four days a week for 8 weeks.

    Behavioral: Inspiratory muscle training

Interventions

  • BehavioralInspiratory muscle training

    Training of respiratory muscles

06

What researchers measure

Primary outcomes

  1. Maximum inspiratory pressure

    Measure of the strength of the inspiratory muscles. Units: cm H20

    Time frame: Baseline to 8 weeks

Secondary outcomes

  1. Physical activity levels

    Number of steps/day averaged weekly.

    Time frame: Baseline to 8 weeks

  2. Modified Medical Research Council Dyspnea scale rating

    Patients will indicate the extent to which their dyspnea affects mobility using a one question 1-5 scale; higher scores indicate greater respiratory disability.

    Time frame: Baseline to 8 weeks

  3. Dyspnea 12 score

    Questionnaire consists of 12 descriptor items such as "I feel short of breath" and "my breathing is uncomfortable" with each item rated on a scale of none (0), mild (1), moderate (2), or severe (3). Individual items are summed to generate a total score (0 to 36), with a higher score indicating worse dyspnea

    Time frame: Baseline to 8 weeks

  4. RAND-36 Quality of life

    8 subdomains will be scored 0-100 with higher scores reflecting better perceived quality of life.

    Time frame: Baseline to 8 weeks

  5. FACIT-F

    Version 4 is a 40-item measure that will be used to assess self-reported fatigue and its impact on daily activities and function over the past 7 days. It is a 5-point Likert-type scale with five subdomains including physical well-being, social/family well-being, emotional well-being, functional well-being, and fatigue yielding a total score from 0-52.

    Time frame: Baseline to 8 weeks

Other outcomes

  1. Relative dose intensity of chemotherapy

    Will record the relative dose intensity of chemotherapy for each participant. The relative dose intensity will be averaged for analysis.

    Time frame: At 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Deidentified data will be freely available if requested. The privacy and rights of the participants will be protected.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will become available after data collection is complete for up to 3 years.

Access criteria: Deidentified data will be made available on request following approved data use agreements between institutions.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.

Of 268 non-industry interventional studies with no phase under Dyspnea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 10 months is below that.

Counting every sponsor, half of 284 studies reached it within 13 months; a quarter within 6 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 4, 2026
StartActual
Feb 16, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07386444
Responsible party
Dharini Bhammar (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Principal investigator
First posted
Feb 4, 2026
Start date
Feb 16, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 6, 2026

Study contacts

The Ohio State University Comprehensive Cancer Center
Contact
OSUCCCClinicaltrials@osumc.edu
800-293-5066
Dharini Bhammar
Contact
dharini.bhammar@osumc.edu
614-366-9467
Dharini M Bhammar, MBBS, PhD
principal investigator · Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion